{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:03:36Z","timestamp":1790269416674,"version":"4.1.0"},"reference-count":87,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This study aimed to systematically evaluate the association between adverse drug reactions, medication adherence, and outpatient treatment outcomes among women with breast cancer receiving oral anticancer therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and guided by the Joanna Briggs Institute methodology. A comprehensive literature search was performed in PubMed, CINAHL Ultimate, Embase, MEDLINE, and Scopus to identify quantitative observational studies published in English from database inception through June 2026. Eligible studies examined the association between adverse drug reactions and medication adherence and\/or outpatient treatment outcomes in female patients with breast cancer receiving oral anticancer therapies. Cohort, case-control, and cross-sectional studies conducted in outpatient settings were included. Two independent reviewers screened studies, extracted data, and assessed methodological quality using Joanna Briggs Institute critical appraisal tools. Meta-analyses were conducted when sufficient clinical and methodological homogeneity was present.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty studies involving 44,455 women were included; all evaluated oral endocrine therapy. Adverse drug reactions were associated with lower medication adherence, although substantial between-study heterogeneity limited confidence in the magnitude and generalizability of the pooled association. Evidence linking adverse drug reactions with outpatient treatment outcomes, including disease-free survival, was limited and heterogeneous, with no consistent association identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adverse drug reactions were associated with medication nonadherence among women receiving oral endocrine therapy. However, the very high heterogeneity of the adherence synthesis and the observational nature of the included studies preclude a precise common-effect or causal interpretation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261487600","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:43:14Z","timestamp":1790066594000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["The association of adverse drug reactions with medication adherence among patients with breast cancer: A systematic review and meta-analysis"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2047-6025","authenticated-orcid":false,"given":"Kuan-Han","family":"Lin","sequence":"first","affiliation":[{"name":"Asia University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2902-3156","authenticated-orcid":false,"given":"Kuan-Yin","family":"Lin","sequence":"additional","affiliation":[{"name":"National Taiwan University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"World Health Organization. Breast Cancer. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer (2024 accessed August 5 2025)."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S176070"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21320"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174287"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.2258"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000534154"},{"key":"e_1_3_3_8_2","article-title":"Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer","volume":"3","author":"Bui KT","year":"2020","unstructured":"Bui KT, Willson ML, Goel S, et al. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer. Cochrane Database Syst Rev 2020; 3: Cd013538. 2020\/03\/07.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.700722"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06368-4"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2017.746"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0405"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2022.01.012"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-019-4651-7"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13312"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05529-3"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-024-01832-9"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/5812817"},{"key":"e_1_3_3_19_2","article-title":"Understanding the dual challenge: adverse drug reactions and adherence in rheumatoid arthritis treatment","volume":"17","author":"Nikose A","year":"2025","unstructured":"Nikose A, Patil S, Kadhe N. Understanding the dual challenge: adverse drug reactions and adherence in rheumatoid arthritis treatment. Cureus 2025; 17: e76712. 2025\/02\/03.","journal-title":"Cureus"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15147"},{"key":"e_1_3_3_21_2","first-page":"578438","article-title":"Impact of Side effects on 5-year adherence to adjuvant endocrine therapy in women with breast cancer","volume":"18","author":"Qiu A","year":"2026","unstructured":"Qiu A, Yang H, Guo J, et al. Impact of Side effects on 5-year adherence to adjuvant endocrine therapy in women with breast cancer. An Integrative Review. Int J Womens Health 2026; 18: 578438. 2026\/03\/12.","journal-title":"An Integrative Review. Int J Womens Health"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1444012"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102264"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2022.04.010"},{"key":"e_1_3_3_25_2","unstructured":"The Joanna Briggs Institute. Critical Appraisal Tools. https:\/\/jbi.global\/critical-appraisal-tools (accessed August 5 2025)."},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0282180"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2021.05.005"},{"key":"e_1_3_3_28_2","unstructured":"Higgins JPTTJ Chandler J Cumpston M et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.5 www.cochrane.org\/handbook (2024 accessed 2025 Nov 12 2025)."},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2012.000543"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1188\/14.ONF.274-285"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.12.006"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30318"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-016-3871-3"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-401"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2017.03.002"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2015.06.010"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/pon.4362"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.18.00091"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-2961-3"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001071"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-4713-2"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy136"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103731"},{"key":"e_1_3_3_44_2","article-title":"Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer","volume":"27","author":"Brett J","year":"2018","unstructured":"Brett J, Fenlon D, Boulton M, et al. Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer. Eur J Cancer Care 2018; 27: e12601.","journal-title":"Eur J Cancer Care"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1037\/hea0000785"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2004.10.005"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt513"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds055"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw266"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4637-2"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn646"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.03.014"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2015.01.010"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2014.04.005"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S167004"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3017"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-019-05201-3"},{"key":"e_1_3_3_58_2","first-page":"113","article-title":"Adherence to hormone therapy in women with breast cancer: a quantitative study","volume":"69","author":"Iacorossi L","year":"2016","unstructured":"Iacorossi L, Gambalunga F, Fabi A, et al. Adherence to hormone therapy in women with breast cancer: a quantitative study. Prof Inferm 2016; 69: 113\u2013121. 2016\/09\/08.","journal-title":"Prof Inferm"},{"key":"e_1_3_3_59_2","first-page":"383","article-title":"Adherence to adjuvant hormonal therapy and associated factors among women with breast cancer attending the tikur anbessa specialized hospital, Addis Ababa Ethiopia, 2019: a cross-sectional study","volume":"13","author":"Wako Z","year":"2021","unstructured":"Wako Z, Mengistu D, Dinegde NG, et al. Adherence to adjuvant hormonal therapy and associated factors among women with breast cancer attending the tikur anbessa specialized hospital, Addis Ababa Ethiopia, 2019: a cross-sectional study. Breast Cancer (Dove Med Press) 2021; 13: 383\u2013392. 2021\/06\/18.","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1002\/pon.4771"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1668-y"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djad109"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-025-07840-1"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-019-05294-w"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.7116"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1718440"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1704927"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.3068"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200209000-00009"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05585-9"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2019.101706"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-023-06989-x"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00697"},{"key":"e_1_3_3_74_2","first-page":"20150608","article-title":"Factors influencing the process of medication (non-)adherence and (non-)persistence in breast cancer patients with adjuvant antihormonal therapy: a qualitative study","volume":"26","author":"Verbrugghe M","year":"2017","unstructured":"Verbrugghe M, Verhaeghe S, Decoene E, et al. Factors influencing the process of medication (non-)adherence and (non-)persistence in breast cancer patients with adjuvant antihormonal therapy: a qualitative study. Eur J Cancer Care 2017; 26: 20150608.","journal-title":"Eur J Cancer Care"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1111\/jan.14253"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-05073-z"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt433"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjhp.12274"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.6926"},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.21037\/apm-21-1878"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1177\/2055102917740469"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2014.10.005"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0304573"},{"key":"e_1_3_3_84_2","article-title":"2018 Hematology\/oncology pharmacist association best practices for the management of oral oncolytic therapy: pharmacy practice standard","volume":"15","author":"Mackler E","year":"2019","unstructured":"Mackler E, Segal EM, Muluneh B, et al. 2018 Hematology\/oncology pharmacist association best practices for the management of oral oncolytic therapy: pharmacy practice standard. JCO Oncol Pract 2019; 15: e346\u2013e355. 2019\/03\/13.","journal-title":"JCO Oncol Pract"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.70934"},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1309702"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.32872\/cpe.v2i1.2695"},{"key":"e_1_3_3_88_2","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-13-0389"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261487600","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261487600","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261487600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:23:51Z","timestamp":1790267031000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261487600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":87,"alternative-id":["10.1177\/10781552261487600"],"URL":"https:\/\/doi.org\/10.1177\/10781552261487600","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"10781552261487600"}}